Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. The company is headquartered in Hayward, California and currently employs 627 full-time employees. The company went IPO on 2018-03-15. The firm has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The firm has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The firm is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). The company is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Follow-Up Questions
Qui est le CEO de Arcus Biosciences Inc ?
Dr. Terry Rosen est le Chairman of the Board de Arcus Biosciences Inc, il a rejoint l'entreprise depuis 2015.
Quelle est la performance du prix de l'action RCUS ?
Le prix actuel de RCUS est de $12.44, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Arcus Biosciences Inc ?
Arcus Biosciences Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Arcus Biosciences Inc ?
La capitalisation boursière actuelle de Arcus Biosciences Inc est de $1.3B
Est-ce que Arcus Biosciences Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 13 analystes ont établi des notations d'analystes pour Arcus Biosciences Inc, y compris 5 achat fort, 11 achat, 3 maintien, 0 vente et 5 vente forte
